Trial Profile
A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Registrational
- Acronyms LUMINANCE
- Sponsors AstraZeneca; AstraZeneca AB
- 23 May 2023 Planned End Date changed from 28 Mar 2024 to 21 Apr 2024.
- 23 May 2023 Planned primary completion date changed from 21 Jun 2023 to 21 Apr 2024.
- 16 Jan 2023 Status changed from recruiting to active, no longer recruiting.